Immunovant Inc (IMVT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Immunovant Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 38.60 $ — 91% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 14.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 902 m net cash passed
- Operating cash flow covers the profits of the last three years 181 m failed
- Return on capital at 15% or higher, or up versus two years ago -62.5% failed
- Insiders hold at least 10% or are net buyers 56.8% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 21.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 03/31/2027 | -2.53 | -2.94 – -1.75 | 0 | -2.4% | 5 |
| 03/31/2028 | -2.13 | -2.47 – -1.24 | 37 | 15.7% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.66 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.76 | – | 0 | – | – | -100 | -101 |
| 2025: Q1 | -0.70 | – | 0 | -89.30 | -66,530.60 | -111 | -111 |
| 2025: Q2 | -0.71 | – | 0 | – | – | -117 | -117 |
| 2025: Q3 | -0.73 | – | 0 | – | – | -103 | -103 |
| 2025: Q4 | -0.61 | – | 0 | – | – | -92 | -92 |
| 2026: Q1 | -0.73 | – | 0 | -100.00 | – | -95 | -95 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | – | 0 | 0 | – | – | – | – |
| 2019 | – | 0 | 0 | 0.00 | -29 | 0 | 0 |
| 2020 | 0 | -60 | -66 | -1.54 | -53 | 94 | 109 |
| 2021 | 0 | -108 | -107 | -1.22 | -83 | 391 | 412 |
| 2022 | 0 | -156 | -157 | -1.43 | -106 | 470 | 516 |
| 2023 | 0 | -208 | -211 | -1.71 | -188 | 362 | 406 |
| 2024 | 0 | -270 | -259 | -1.88 | -214 | 618 | 667 |
| 2025 | 0 | -438 | -414 | -2.73 | -376 | 707 | 776 |
| 2026 | 0 | -533 | -506 | -2.77 | -407 | 853 | 958 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Immunovant, Inc., ein Immunologieunternehmen im klinischen Stadium, entwickelt gezielte Therapien für die Bedürfnisse von Menschen mit Autoimmunerkrankungen.
| Employees | 315 |
|---|---|
| Headquarters | Durham, NC |
| Address | 1000 Park Forty Plaza, 27713 Durham, United States |
| Phone | 917 410 3120 |
| Website | immunovant.com |
| IPO Date | 21. Jun 2019 |
| ISIN | US45258J1025 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 1979 |
| Eric Venker M.D., Pharm.D. | CEO & Director | 1987 |
| Christine Blodgett | Senior Vice President of Human Resources | – |
| Becky Merlina | Senior VP & Global Head of Quality | – |
| Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | – |
| Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | – |
| Khira Gabliani M.B.A. | Chief of Staff to the CEO | – |
| Luciano Pollastrini M.S. | Senior Vice President of CMC Technical Operations | – |
| Lorna Liganor | Senior Vice President of Clinical Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 23. Apr 2026 | Jay S Stout | CTO | Sell | 2,754 | 29.62 | 81,573 |
| 23. Apr 2026 | Tiago Girao | CFO | Sell | 25,760 | 29.62 | 763,011 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.